Trial Profile

Estudio fase II, abierto, multicentrico, no aleatorizado para evaluar la eficacia y la seguridad de la combinacion de lapatinib, oxaliplatino y capecitabina como tratamiento neoadyuvante en pacientes HER2/ErbB2 positivo con adenocarcinoma gastrico, de la union gastroesofagica o del tercio inferior del esofago, en estadio IB-III.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 31 Mar 2012

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Mar 2012 Status changed from recruiting to discontinued according to EudraCT record..
28 Jun 2011 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com